




Oncology



NCCN 2022

# Gilead Oncology Presentations

## A Phase 2, Multi-Arm Study of Anti-CD47 Antibody Magrolimab in Combination with Docetaxel in Patients with Locally Advanced or Metastatic Solid Tumors

Vivek Subbiah; Ulka Vaishampayan; Sonam Puri; Lanjia Lin; Mark Chao; Giri Ramsingh; Shivaani Kummar; James F. Strauss; Sandip P. Patel

## A Phase 2 Study of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Dimitrios Colevas, John J. Park, Bruno Fang, Jiang Shao, Lance U'Ren, Jared Odegard, Indu Lal, Minh Phan, Kyaw Z. Thein, Douglas Adkins

**The safety and efficacy of these investigational agents and/or uses have not been established.  
There is no guarantee that they will become commercially available.**

